세계의 폰다파리눅스(Fondaparinux) 시장 규모 분석 : 유형별, 용도별, 유통 채널별, 지역별 예측(2022-2032년)

The global fondaparinux market was valued at approximately USD 652.6 million in 2023 and is anticipated to experience robust growth at a CAGR of 6.9% during the forecast period of 2024-2032. The rising geriatric population worldwide, along with the increasing prevalence of deep vein thrombosis (DVT), pulmonary embolism (PE), and cardiovascular diseases (CVDs), is driving the demand for fondaparinux. As a synthetic anticoagulant, fondaparinux plays a critical role in the prevention and treatment of blood clot formation, particularly after major surgeries such as hip and knee replacements. The growing awareness regarding venous thromboembolism (VTE) and an increase in post-surgical prophylaxis use are further expected to contribute to market expansion.

The World Health Organization (WHO) estimates that CVDs are the leading cause of mortality worldwide, accounting for approximately 18 million deaths annually. A significant proportion of these deaths result from heart attacks and strokes, particularly among the elderly. The demand for effective anticoagulants like fondaparinux is rising as healthcare providers seek efficient, easy-to-administer, and safe treatment alternatives to conventional anticoagulants such as heparin. Additionally, branded versions such as Arixtra are gaining traction due to their enhanced efficacy and lower risk of internal bleeding, further bolstering market growth.

The generic segment dominated the fondaparinux market in 2023, accounting for a revenue share of 68.8%. This is attributed to affordable pricing, increased market accessibility, and a growing preference among healthcare providers for cost-effective alternatives. However, branded drugs continue to command a steady market share, driven by high consumer trust, rigorous clinical assessments, and regulatory approvals. Despite higher costs, patients suffering from severe cardiovascular complications or complex surgical recovery often opt for branded medications, supporting segment growth.

Regionally, North America held the largest market share in 2023, primarily due to a well-established healthcare infrastructure, a high prevalence of cardiovascular diseases, and increasing awareness of anticoagulant therapies. The Asia Pacific market is projected to witness the fastest growth, fueled by a rapidly aging population, increasing healthcare expenditure, and growing incidences of thrombosis-related conditions. Countries such as China, India, and Japan are experiencing a surge in demand for fondaparinux-based treatments, supported by governmental healthcare reforms and expanding pharmaceutical distribution networks.

Major Market Players Included in This Report:

• GlaxoSmithKline plc (GSK)
• Abbott Laboratories Inc.
• Dr. Reddy's Laboratories Ltd.
• Lupin Pharmaceuticals Inc.
• Apotex Inc.
• Alchemia Limited
• ScinoPharm Taiwan Ltd.
• Mylan N.V.
• Sanofi S.A.
• Pfizer Inc.
• Novartis AG
• Sandoz International GmbH
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Cipla Ltd.

The Detailed Segments and Sub-Segment of the Market Are Explained Below:

By Type:

• Branded
• Generic

By Application:

• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Acute Coronary Syndrome
• Other Applications

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East & Africa
• Saudi Arabia
• UAE
• South Africa
• Kuwait

Years Considered for the Study:

• Historical Year - 2022
• Base Year - 2023
• Forecast Period - 2024 to 2032

Key Takeaways:

• Market estimates & forecasts for 10 years from 2022 to 2032.
• Annualized revenue and regional-level analysis for each segment.
• Detailed geographical landscape with country-level market insights.
• Competitive landscape with insights into leading players, mergers, acquisitions, and product launches.
• Market structure analysis and strategic recommendations for new entrants.
• Demand-side and supply-side market trends.

Table of Contents

Chapter 1. Global Fondaparinux Market Executive Summary

• 1.1. Global Fondaparinux Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Type
  • 1.3.2. By Application
  • 1.3.3. By Distribution Channel
• 1.4. Key Market Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendations & Conclusion

Chapter 2. Global Fondaparinux Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory Frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Fondaparinux Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Rising Prevalence of Deep Vein Thrombosis and Cardiovascular Diseases
  • 3.1.2. Increasing Aging Population and Higher Healthcare Expenditure
  • 3.1.3. Preference for Synthetic Anticoagulants Over Conventional Heparin-Based Treatments
• 3.2. Market Challenges
  • 3.2.1. High Cost of Branded Fondaparinux Medications
  • 3.2.2. Regulatory Compliance and Patent Expiry Issues
• 3.3. Market Opportunities
  • 3.3.1. Expansion of Online Pharmacies and Telemedicine Consultations
  • 3.3.2. Growth in Emerging Economies with Expanding Healthcare Infrastructure

Chapter 4. Global Fondaparinux Market Industry Analysis

• 4.1. Porter's Five Forces Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economic
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunities
• 4.4. Emerging Market Trends
• 4.5. Analyst Recommendations & Conclusion

Chapter 5. Global Fondaparinux Market Size & Forecasts by Type (2022-2032)

• 5.1. Segment Dashboard
• 5.2. Global Fondaparinux Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 5.3. Branded
• 5.4. Generic

Chapter 6. Global Fondaparinux Market Size & Forecasts by Application (2022-2032)

• 6.1. Segment Dashboard
• 6.2. Global Fondaparinux Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 6.3. Deep Vein Thrombosis (DVT)
• 6.4. Pulmonary Embolism (PE)
• 6.5. Acute Coronary Syndrome
• 6.6. Other Applications

Chapter 7. Global Fondaparinux Market Size & Forecasts by Distribution Channel (2022-2032)

• 7.1. Segment Dashboard
• 7.2. Global Fondaparinux Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 7.3. Hospital Pharmacies
• 7.4. Retail Pharmacies
• 7.5. Online Pharmacies

Chapter 8. Global Fondaparinux Market Size & Forecasts by Region (2022-2032)

• 8.1. North America Fondaparinux Market
  • 8.1.1. U.S.
  • 8.1.2. Canada
  • 8.1.3. Mexico
• 8.2. Europe Fondaparinux Market
  • 8.2.1. UK
  • 8.2.2. Germany
  • 8.2.3. France
  • 8.2.4. Italy
  • 8.2.5. Spain
  • 8.2.6. Denmark
  • 8.2.7. Sweden
  • 8.2.8. Norway
• 8.3. Asia Pacific Fondaparinux Market
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. India
  • 8.3.4. South Korea
  • 8.3.5. Australia
  • 8.3.6. Thailand
• 8.4. Latin America Fondaparinux Market
  • 8.4.1. Brazil
  • 8.4.2. Argentina
• 8.5. Middle East & Africa Fondaparinux Market
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. South Africa
  • 8.5.4. Kuwait

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. GlaxoSmithKline plc (GSK)
  • 9.1.2. Abbott Laboratories Inc.
  • 9.1.3. Dr. Reddy's Laboratories Ltd.
• 9.2. Top Market Strategies
• 9.3. Company Profiles

Chapter 10. Research Process

• 10.1. Research Methodology
  • 10.1.1. Data Collection and Primary Research
  • 10.1.2. Secondary Research
  • 10.1.3. Market Forecasting & Validation
  • 10.1.4. Data Triangulation
• 10.2. Market Size Estimation
  • 10.2.1. Bottom-Up Approach
  • 10.2.2. Top-Down Approach
• 10.3. Research Assumptions & Limitations